How is Creative Biolabs' PTM analysis superior to standard Western Blot or RNA-seq for target validation?

Western Blot is often semi-quantitative, and RNA-seq only measures transcription. Our PTM analysis is fully quantitative, measuring the activating phosphorylation stoichiometry (p-protein/total-protein ratio). This provides the definitive, functional measure of pathway activity needed to confirm true drug engagement and quantify the inhibition needed for research efficacy.

Can this service help identify which experimental models might respond best to Immunotherapy?

Absolutely. ICI failure in research models is often due to tumor-intrinsic resistance driven by oncogene activity (e.g., active WNT signaling causes T-cell exclusion, and JAK/STAT mutations impair IFN-γ response). Our service functionally measures these resistance drivers, allowing you to select combination partners that will re-sensitize the tumor models to immunotherapy.

Oncogene Pathway Activity Analysis Service

The oncogene pathway activity analysis service offered by Creative Biolabs furnishes research teams with a high-resolution, quantitative representation of the functional signaling architecture within their investigational models. This service incorporates a fully customizable methodology, focusing on the quantitative measurement of activity across critical oncogenic pathways to elucidate complex mechanisms of acquired resistance and pathway-mediated crosstalk. Utilization of this service yields actionable insights regarding compound efficacy, provides validated pharmacodynamic (PD) markers, and generates robust evidence necessary for the rational development of optimized combination strategies, thereby ensuring expedited progress within the research pipeline.

Functional Quantification of Oncogenic Pathways

Precision oncology requires the targeted modulation of the cancer cell's functional infrastructure, driven by hyperactive signaling. The Oncogene Pathway Activity Analysis Service precisely quantifies the functional status of essential cancer drivers by measuring post-translational modifications (PTMs), particularly phosphorylation. This analytical strategy is robustly substantiated by literature confirming that genetic dysregulation in pathways like RAS/MAPK and PI3K/AKT contributes to drug resistance and tumor-intrinsic immune evasion.

Fig 1. Molecular pathways affected during PC. (OA Literature)

Fig.1 The RAS/RAF/MEK/ERK and PI3K/AKT pathways' abnormal activation in pancreatic cancer. ¹

What We Can Offer

Ultimate Functional Readout

We provide a definitive functional readout through the quantification of critical post-translational modifications, specifically activating phosphorylation sites, across the ten canonical oncogenic pathways, thereby measuring cellular activity with precision.

Proprietary Crosstalk Mapping

Our proprietary assays facilitate instantaneous detection and precise quantification of compensatory pathway activation, such as PI3K/AKT activity following MAPK blockade, thereby elucidating latent mechanisms of therapeutic resistance.

Customized Panel Design

The design of custom panels involves fully adaptable assay development for novel targets, mutated proteins, or unique signaling cascades, ensuring precise tailoring to the client's therapeutic pipeline and specific model system requirements.

Quantitative Stoichiometry

Quantification of the precise p-protein to total-protein ratio (stoichiometry) is employed, which guarantees superior data accuracy and precision when contrasted with conventional, typically semi-quantitative, analytical methods such as Western Blotting.

Oncogene Pathway Activity Analysis at Creative Biolabs

Highlights

Years of PTM Expertise

Leveraging over two decades of PTM expertise, the organization maintains its position as a pioneer in quantitative phospho-proteomics, ensuring optimal sensitivity for the accurate detection of low-abundance, transient phosphorylation events.

Integrated Multi-Pathway View

The integrated platform concurrently assesses the ten canonical oncogenic pathways, thereby providing a holistic view. This comprehensive analysis precisely identifies pathway crosstalk, such as PI3K/AKT compensation, which mediates resistance to single-agent therapeutics.

ICI Resistance Expertise

Direct assessment of functional immune evasion markers, including WNT activity and JAK/STAT integrity, facilitates a mechanism-based strategy. This enables the rational combination of targeted agents with immune checkpoint inhibitors (ICIs).

Rigorous Validation

Each assay undergoes rigorous optimization and cross-validation utilizing established published data. This process substantiates the relevance of the functional assays for accurate sample characterization and prognostic determination across tumor types.

Customer Reviews

FAQs

Related Services

Kinase Selectivity Profiling

This service provides comprehensive, broad-spectrum screening of therapeutic compounds against expansive panels of wild-type and mutant kinases. The goal is to accurately determine compound specificity, potency, and any potential off-target liabilities in early-stage research.

Learn More →

Efficacy Models

We offer quantitative functional analysis, including PTM and multi-cytokine profiling, of immune cells within the tumor microenvironment. This analysis reveals the immune status and exclusion mechanisms, which are essential for successful IO efficacy modeling.

Learn More →

How to Contact Us

Creative Biolabs' commitment to high-end scientific rigor ensures your therapeutic assets are evaluated using the most sensitive and relevant functional and individualized assays available. Ready to quantify the functional activity of your targets and accelerate your path to the next stage of development? Our expert team is prepared to design a customized pathway analysis study tailored to your therapeutic pipeline. Please contact us.